Ye Weiguo sold $17K of GYRE
Ye Weiguo (Chief Operating Officer) sold 2,800 shares of GYRE THERAPEUTICS, INC. (GYRE) at $6.17 on 2026-06-11.
How this was made
The 30-second read
Why it matters
Provides a fresh datapoint on insider selling activity; without accompanying company news, it mainly informs sentiment and positioning rather than valuation.
Market read
Traders may briefly reassess near-term sentiment around GYRE due to insider selling, but the filing lacks fundamental catalysts.
What to watch
No 10b5-1 plan is cited; traders may watch for subsequent insider buys/sales or other filings (e.g., financing, trial updates) to confirm whether this is meaningful.
Background
The article is an SEC EDGAR Form 4 insider transaction disclosure for GYRE Therapeutics.
Ticker impact
SEC Form 4 shows COO Ye Weiguo sold 2,800 shares of GYRE Therapeutics at $6.17 on 2026-06-11.
Likely limited near-term impact; any effect would be incremental and fade unless followed by additional disclosures.
The filing is a routine insider sale (no 10b5-1 plan stated) with small absolute size relative to typical institutional flows, and it provides no new operating/clinical/regulatory information.
Market effects
No sector-level read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
The sale may be for diversification/tax/regular liquidity needs and does not necessarily reflect negative fundamentals.
Key entities
- issuerGYRE THERAPEUTICS, INC.
Company whose COO insider sale is disclosed on Form 4.
- insiderYe Weiguo
Chief Operating Officer who sold 2,800 shares on 2026-06-11.